Cargando…
Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets
Hepatocellular carcinoma (HCC) remains a global medical burden with rising incidence due to chronic viral hepatitis and non-alcoholic fatty liver diseases. Treatment of advanced disease stages is still unsatisfying. Besides first and second generation tyrosine kinase inhibitors, immune checkpoint in...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Baishideng Publishing Group Inc
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6626722/ https://www.ncbi.nlm.nih.gov/pubmed/31333307 http://dx.doi.org/10.3748/wjg.v25.i25.3136 |